Figure 4
From: Serelaxin improves cardiac and renal function in DOCA-salt hypertensive rats
Serelaxin decreased kidney inflammation. Quantitative real-time PCR (qRT-PCR) analysis showed that treatment with serelaxin prevented the increases in the inflammatory markers (a) IL-1-β, (b) IL-6, (c) ICAM-1, (d) VCAM-1, (e) MCP-1, and (f) NFκB mRNA. Serelaxin also prevented the increases in (g) CD68 immunostaining and (h) phospho-NFκB protein abundance in the kidney. Equal protein loading was verified by using an anti-β-actin antibody. The detection was executed by an ECL western blotting analysis system. Whole bolts are reported in Supplemental Fig. 1. Results are expressed as means ± SEM (n = 6 rats for qRT-PCR, n = 3 for western blot). Statistical analysis was performed with one-way ANOVA.
